PT  - JOURNAL ARTICLE
AU  - GLAESER, MICHAEL
AU  - NIEDERACHER, DIETER
AU  - DJAHANSOUZI, SIRUS
AU  - HANSTEIN, BETTINA
AU  - DITTRICH, RALF
AU  - BECKMANN, MATTHIAS W.
AU  - FASCHING, PETER A.
AU  - ACKERMANN, SVEN
TI  - Effects of the Antiestrogens Tamoxifen and Raloxifene on the Estrogen Receptor Transactivation Machinery
DP  - 2006 Jan 01
TA  - Anticancer Research
PG  - 735--744
VI  - 26
IP  - 1B
4099  - http://ar.iiarjournals.org/content/26/1B/735.short
4100  - http://ar.iiarjournals.org/content/26/1B/735.full
SO  - Anticancer Res2006 Jan 01; 26
AB  - The influence of 17β-estradiol (E2), tamoxifen (TAM) and raloxifen (RLX) on the proliferation of breast (BC) and endometrial carcinoma cell lines (EC) and the expression of different compounds of the estrogen receptor (ER)-transactivation machinery were studied. E2 stimulated the proliferation of BC, but had no effect on the EC. TAM showed a biphasic effect on ER-positive cell lines. RLX showed an antagonistic suppression or no effect. The expression of ERα was down-regulated by E2, but not affected by selective estrogen receptor modulators. ERβ and progesterone receptor expressions were up-regulated by E2, TAM and OHT. This supports the hypothesis that ERβ expression is also regulated via the ERα-pathway. The steroid receptor coactivator (SRC) AIB1 expression was slightly decreased by E2 but not by antiestrogens (antiE). TIF2 expression was increased by E2, TAM and RLX, but SRC-1 expression was not. In comparison, the expressions of ERβ and progesterone receptor were strongly influenced by antiE, while the expression of SRCs was only slightly affected. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved